TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference

Stock News

昨天

TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1106629682"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106629682\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106629682?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106629682","market":"fut","top_or_hot":-1,"title":"TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYK MEDICINES-B to Present Findings from Five Novel Drug Programs at 2026 AACR Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-25 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1106629682","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106629682","pubTimestamp":1774449860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","159992":"创新药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","06978":"永泰生物-B","02410":"同源康医药-B","BK1574":"生物医药B类股"},"translate_title":"TYK MEDICINES-B将在2026年AACR会议上展示五个新药项目的研究结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"159992":1,"09939":1,"02410":1,"06978":1},"content_text":"TYK MEDICINES-B (02410) has announced that the company will present research progress and results for five innovative drug candidates during the poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The projects to be showcased include TY-0609 (a CDK4 inhibitor), TY-2699a (a CDK7 inhibitor), TY-2719 (an EGFR/FAK (PROTAC) inhibitor), a PI3Kα inhibitor, and TY-1054 (a YAP-TEAD inhibitor). All five programs represent self-developed small molecule anti-tumor innovative candidate drugs. The 2026 AACR Annual Meeting is scheduled to take place from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be displayed from April 19 to April 21.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}